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A B S T R A C T
Background: Our goal was to perform an extensive systematic review of the literature on the use of
electroconvulsive therapy (ECT) for refractory status epilepticus (RSE).
Methods: Articles from MEDLINE, BIOSIS, EMBASE, Healthstar, Global Health, Scopus, Cochrane Library,
the International Clinical Trials Registry Platform, clinicaltrials.gov (inception to August 2015), reference
lists of relevant articles, and gray literature were searched. The strength of evidence was adjudicated
using both the Oxford and GRADE methodology by two independent reviewers.
Results: We identiﬁed 14 original articles with a total of 19 patients receiving ECT for RSE. Of the 19
patients, 15 were adult, and 4 were pediatric. All studies were retrospective in nature. Seizure reduction/
control with the application of ECT occurred in 11 of the 19 patients (57.9%), with 4 (21.0%) and 7 (36.8%)
displaying partial and complete responses respectively. Seizures control lasted for variable duration,
with the most commonly quoted duration ranging from 2 weeks to 3 months. Data on patient functional
outcome was available in 13 patients, with 10 patients falling into the categories of dead or severely
disabled. All studies were an Oxford level 4, GRADE D level of evidence.
Conclusions: Oxford level 4, GRADE D evidence exists to suggest an improvement in seizure control with
ECT application for RSE. Routine use of ECT cannot be recommended at this time. Further prospective
study of this therapy is required in order to determine its efﬁcacy in this setting.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
Seizure
jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Electroconvulsive therapy (ECT) involves transcutaneous elec-
trical stimulation of the cerebral cortex in order to induce a seizure* Corresponding author. Tel.: +1 204 228 6623; fax: +1 204 787 3851.
E-mail addresses: umzeiler@myumanitoba.ca (F.A. Zeiler),
matuszcm@myumanitoba.ca (M. Matuszczak), jteitelbaum@hotmail.com
(J. Teitelbaum), gillmanlm@gmail.com (L.M. Gillman),
ckazina@exchange.hsc.mb.ca (C.J. Kazina).
1 Martin Matuszczak, Undergraduate Medicine, University of Manitoba, Winni-
peg, MB, Canada, R3A 1R9.
2 Montreal Neurological Institute, 3801 rue University, Montre´al, QC, Canada,
H3A 2B4.
3 Section of General Surgery and Critical Care Medicine, Z3053 St. Boniface
General Hospital, Winnipeg, MB, Canada.
4 Section of Neurosurgery, GB-1 820 Sherbrook Street, Winnipeg, MB, Canada,
R1A1R9.
http://dx.doi.org/10.1016/j.seizure.2015.12.015
1059-1311/ 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights relike episode. The applications of ECT are predominantly rooted in
refractory psychiatric illness, with efﬁcacy documented medically
refractory depression and schizophrenia1,2.
The exact mechanism of action of ECT in the setting of
psychiatric illness is poorly understood despite its long standing
application3–5. It is theorized that ECT leads to alterations in
neurotransmitter levels and an elevation in the seizure threshold
post treatment. Increased gamma aminobutyric acid (GABA)
mediate inhibition of action potential propagation has been
suggested3,5. Furthermore, the potential for a neuroendocrine
mediated effect on neuronal function has been eluded to6. In the
setting of seizure control utilizing ECT, the mechanism of action is
even more elusive, though likely can be attributed to the above
mentioned theories.
The use of ECT in the treatment of SE/RSE has been mentioned
only in reference to salvage therapies for super refractory status
epilepticus (SRSE)7,8. To date however there are only a small
number of cases describing the use of ECT for SE/RSE9–23.served.
F.A. Zeiler et al. / Seizure 35 (2016) 23–3224A recent review in 2012 by Lambrecq et al. attempted to
summarize the available literature on ECT in RSE utilizing a limited
search24. This review displayed 11 cases based on the search
strategy. However, the search excluded a large number of major
health sciences databases and failed to evaluate the published
meeting proceedings of the major relevant professional societies.
Thus, there was the potential for missing some published reports
on the subject.
Our goal was to perform an extensive systematic review of the
available literature on the use of ECT for RSE in order to better
deﬁne its impact on seizure control.
2. Materials and methods
A systematic review using the methodology outlined in the
Cochrane Handbook for Systematic Reviewers25 was conducted.
The data was reported following the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA)26. The review
questions and search strategy were decided upon by the primary
author (FZ) and supervisor (CK).
2.1. Search question, population, inclusion and exclusion criteria
The question posed for systematic review was: What is the
effectiveness of ECT for seizure control in SE/RSE? The deﬁnition of
SE and RSE was as per the Neurocritical Care Society guidelines on
the management of SE27. The term generalized refractory status
epilepticus (GRSE) was used to refer to generalized tonic-clonic
RSE. The term focal refractory status epilepticus (FRSE) was used to
refer focal tonic-clonic RSE. The term multi-focal refractory status
epilepticus (MFRSE) was used to refer to RSE that had a mutli-focal
tonic-clonic nature. The term non-convulsive refractory status
epilepticus (NCRSE) was used for non-convulsive seizures that
fulﬁlled the criteria for RSE. Seizure cessation to ECT was deﬁned as
the absence of seizures for at least a 24 h period.
All studies, prospective and retrospective of any size based on
human subjects were included. The reason for an all-inclusive
search was based on the small number of studies of any type
identiﬁed by the primary author during a preliminary search of
MEDLINE.
The primary outcome measure was electrographic seizure
control, deﬁned as: complete resolution, partial seizure reduction,
and failure. This qualitative seizure response grading was used
given the lack of detail around the electroencephalographic
response reported within the studies found. Secondary outcome
measures were patient outcome (if reported), and adverse events
related to the use of ECT.
Inclusion criteria were: All studies including human subjects
whether prospective or retrospective, all study sizes, any age
category, and the documented use of ECT for the purpose of seizure
control in the setting of SE/RSE. Exclusion criteria were: animal and
non-English studies.
2.2. Search strategy
MEDLINE, BIOSIS, EMBASE, Global Health, Healthstar, SCOPUS,
and Cochrane Library from inception to August 2015 were
searched using individualized search strategies for each database.
The search strategy for MEDLINE can be seen in Appendix A of the
supplementary material, with an identical search strategy utilized
for the other databases. In addition, the World Health Organiza-
tions International Clinical Trials Registry Platform and Clinical-
Trials.gov were searched looking for studies planned or underway,
with none identiﬁed.
As well, meeting proceedings for the last 10 years looking for
ongoing and unpublished work based on ECT for SE/RSE wereexamined. The meeting proceedings of the following professional
societies were searched: Canadian Neurological Sciences Federa-
tion (CNSF), American Association of Neurological Surgeons
(AANS), Congress of Neurological Surgeons (CNS), European
Neurosurgical Society (ENSS), World Federation of Neurological
Surgeons (WFNS), American Neurology Association (ANA), Ameri-
can Academy of Neurology (AAN), European Federation of
Neurological Science (EFNS), World Congress of Neurology
(WCN), Society of Critical Care Medicine (SCCM), Neurocritical
Care Society (NCS), World Federation of Societies of Intensive and
Critical Care Medicine (WFSICCM), American Society for Anesthe-
siologists (ASA), World Federation of Societies of Anesthesiologist
(WFSA), Australian Society of Anesthesiologists, International
Anesthesia Research Society (IARS), Society of Neurosurgical
Anesthesiology and Critical Care (SNACC), Society for Neuroscience
in Anesthesiology and Critical Care, and the Japanese Society of
Neuroanesthesia and Critical Care (JSNCC).
Finally, reference lists of any review articles or systematic
reviews on seizure management were reviewed for relevant
studies on ECT application for SE/RSE that were missed during the
database and meeting proceeding search.
2.3. Study selection
Utilizing two reviewers (FZ and MM), a two-step review of all
articles returned by our search strategies was performed. First, the
reviewers independently screened all titles and abstracts of the
returned articles to decide if they met the inclusion criteria.
Second, full text of the chosen articles was then assessed to conﬁrm
if they met the inclusion criteria and that the primary outcome of
seizure control was reported in the study. Any discrepancies
between the two reviewers were resolved by a third party (CK).
2.4. Data collection
Data was extracted from the selected articles and stored in an
electronic database. Data ﬁelds included: patient demographics,
type of study (prospective or retrospective), number of patients,
type of ECT electrode used, stimulation parameters, timing to
implementation of ECT, duration of ECT therapy, time to effect of
ECT, how many other AED were utilized prior to implementation of
ECT, degree of seizure control (as described previously), adverse
effects, and patient outcome.
Patient outcome was graded according to the original Glasgow
Outcome Scale (GOS) score, with a score of 1 indicating complete
recovery and a score of 5 indicating death35.
2.5. Quality of evidence assessment
Assessment of the level of evidence for each included study was
conducted by a panel of two independent reviewers, utilizing the
Oxford criteria28 and the Grading of Recommendation Assessment
Development and Education (GRADE) criteria29–34 for level of
evidence. We elected on utilizing two different systems to grade
level of evidence given that these two systems are amongst the
most commonly used. We believe this would allow a larger
audience to follow our systematic approach in the setting of
unfamiliarity with a particular grading system.
The Oxford criteria consist of a 5 level grading system for
literature. Level 1 is split into subcategories 1a, 1b, and 1c which
represent a systematic review of randomized control trials (RCT)
with homogeneity, individual RCT with narrow conﬁdence
interval, and all or none studies respectively. Oxford level 2 is
split into 2a, 2b, and 2c representing systematic review of cohort
studies with homogeneity of data, individual cohort study or low
quality RCT, and outcomes research respectively. Oxford level 3 is
F.A. Zeiler et al. / Seizure 35 (2016) 23–32 25split into 3a and 3b representing systematic review of case-control
studies with homogeneity of data and individual case-control
study respectively. Oxford level 4 represents case-series and poor
cohort studies. Finally, Oxford level 5 represents expert opinion.
The GRADE level of evidence is split into 4 levels: A, B, C and D.
GRADE level A represents high evidence with multiple high quality
studies having consistent results. GRADE level B represents
moderate evidence with one high quality study, or multiple low
quality studies. GRADE level C evidence represents low evidence
with one or more studies with severe limitations. Finally, GRADE
level D represents very low evidence based on either expert
opinion or few studies with severe limitations.
Any discrepancies between the grading of the two reviewers (FZ
and MM)were resolved via a third party (CK).
2.6. Statistical analysis
A meta-analysis was not performed in this study due to the
heterogeneity of data within the articles and the presence of a
small number of low quality retrospective studies.
3. Results
The results of the search strategy are summarized in Fig. 1. A
total of 474 articles were identiﬁed, with 471 from the databaseFig. 1. Flow diagram search and 3 from published meeting proceedings. After removing
duplicates, there were 351 articles. By applying the inclusion/
exclusion criteria to the title and abstract, we identiﬁed 28 articles
with 35 from the database search and 3 from meeting proceedings.
Applying the inclusion/exclusion criteria to the full text docu-
ments, 15 articles were eligible for inclusion in the systematic
review, with 12 from database and 3 from meeting proceeding
sources. The articles that were excluded were done so because they
either did not report details around the application of ECT for
seizure control in RSE, or because they were review articles.
Reference sections from these review articles were searched for
any other articles missed in the database search, with 0 being
identiﬁed.
Of the 15 articles included in the review9–23, 14 were original
studies9–22 with 1 companion publication23 containing duplicate
patient data. Shin et al23 was a meeting proceeding describing the
same patient within the manuscript publication Shin et al20. Thus,
the data from Shin et al23 was not included in the ﬁnal analysis in
order to prevent duplication of patient data.
All 14 original studies were retrospective studies9–22, with
3 retrospective case series12,13,16 and 11 retrospective case
reports9–11,14,15,17–22.
Across all studies, a total of 19 patients were documented as
having received ECT for RSE (mean 1 patient/study; range: 1–3
patients/study). Four patients were pediatric with a mean age of 10of search results.
Table 1
Study Characteristics and Patient Demographics.
Reference Number of patients
treated with ECT
Study type/
design
Article location Mean age
(years)
Etiology of seizures and type of
SE/RSE
Mean # meds
prior to ECT
Mean time
until ETC
treatment
(days)
Carrasco et al.9 1 Retrospective
Case report
Journal
Manuscript
25 Etiology: post traumatic changes to
frontal/temporal lobes
Type: GRSE
5 40
Cline et al.10 1 Retrospective
Case Report
Journal
Manuscript
39 Etiology: HSV encephalitis
Type: GRSE
8 103
Fernandez-Torre et al.11 1 Retrospective
case Report
Journal
Manuscript
59 Etiology: post traumatic epilepsy
Type: FRSE
14 >25
Griesemer et al.12 2 Retrospective
Case Series
Journal
Manuscript
11.5 (13 yrs and
10 yrs)
1!Etiology: microgyria
Type: GRSE
2! Etiology: microcephaly
Type: FRSE
5 (8 and 2) NA
Kamel et al.13 3 Retrospective
Case Series
Journal
Manuscript
33 (32, 41, and
26 yrs)
1! Etiology: viral encephalitis
Type: GRSE
2! Etiology: viral encephalitis
Type: GRSE
3! Etiology: infectious cerebritis
Type: GRSE
7 (6, 5, and 7) 44
Koong et al.14 1 Retrospective
Case Report
Journal
Manuscript
54 Etiology: epilepsy with psychosis
Type: NCRSE
4 NA
Lisanby et al.15 1 Retrospective
Case Report
Journal
Manuscript
36 Etiology: bifrontal cortical dysplasia
Type: FRSE
7 26
Moddel et al.16 3 Retrospective
Case Series
Meeting
Abstract
68 (59, 65, and
80 yrs)
1! Etiology: bitemporal encephalitis
Type: NCRSE
2! Etiology: resection of meningiomas
Type: GRSE
3! Etiology: subdural hematoma
Type: GRSE
8 (8, 9, and 6) 44
Morales et al.17 1 Retrospective
Case Report
Journal
Manuscript
8 Etiology: lipofuscinosis
Type: FRSE
7 NA
Regenold et al.18 1 Retrospective
Case Report
Journal
Manuscript
71 Etiology: primary epilepsy
Type: FRSE
5 9
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F.A. Zeiler et al. / Seizure 35 (2016) 23–32 27years (age range: 7 years to 13 years). Fifteen patients were adult
with a mean age of 44 years (age range: 19 to 80 years).
Seizures were classiﬁed as GRSE in 9 patients9,10,12,13,16,19, FRSE
in 7 patients11,12,15,17,18,21,22, and NCRSE in 3 patient14,16,20. The
etiology of RSE varied signiﬁcantly.
Study demographics and patient characteristics for all studies
can be seen in Table 1, while treatment characteristics and seizure
outcome are reported in Table 2.
3.1. ECT treatment characteristics
Twelve of the 14 original articles provided9,10,12–18,20–22 details
around the treatment parameters for ECT. The remaining 2 studies
only referred to the use of ECT in the management of RSE, without
providing treatment parameters11,19.
Electrode position was bifrontotemporal in 4 patients10,13,
‘‘bilateral’’ in 3 patients17,18,20, and mixed in 1 patient15. In eleven
patients the electrode position for the ECT treatment was not
described9,11,12,14,16,19,21,22.
The number of treatment sessions with ECT was highly variable
across the studies included in the review. The most commonly
described session frequency was 1 per day. The most common
treatment duration with ECT lasted approximately 1 week, with
daily sessions.
Duration of treatment prior to implementation of ECT therapy
was documented in 7 articles9,10,13,15,16,18,20, ranging from 9 to 103
days (mean = 40 days). The remaining 7 articles failed to mention
the duration of therapy prior to implementation of
ECT11,12,14,17,19,21,22. The number of AEDs administered prior to
ECT was documented in all studies, with the total number ranging
from 2 to 14 (mean = 7). Detailed ECT treatment characteristics can
be seen in Table 2.
3.2. Seizure response
Seizure response to ECT occurred in 11 of the 19 patients
(57.9%) included in the review, with 4 patients10,12,13 (21.0%)
displaying partial EEG based response and 7 patients9,13–15,18,20,21
(36.8%) displaying complete resolution of seizures. Eight of the 19
patients (42.1%) had no response to ECT therapy3,11,16,17,19,22.
Looking at seizure subtype: 5 of the 9 (55.5%) GRSE patients
responded, 4 of the 7 (57.1%) FRSE patients responded, and 2 of the
3 (66.6%) NCRSE patients responded.
The time from ECT response to recurrence of seizure activity
was recorded in some studies. The duration of response to ECT
therapy varied from 2 days up to 8 years. The most common
duration of seizure control with ECT was 2 weeks to 3 months.
3.3. Adverse effects of ECT
Adverse events related to ECT therapy were documented in 4
studies12,13,17,18. Two studies stated ‘‘no adverse events’’ were
seen17,18. Three patients had transient lethargy or amnestic
events12,13. No cardiac arrest or respiratory complications were
reported. The remaining 10 studies did not document adverse
events9–11,14–16,19–22.
3.4. Outcome
Outcome data was recorded in 10 of the 14 studies9–11,13,15–
17,19–21. Data on patient outcome was available in only 13 of the 19
(68.4%) of the patients treated. Glasgow OutcomeScale35 scores
were approximated based on the available data within the reports,
with GOS scores of 5, 4, 3, 2, or 1 recorded in 2 (10.5%), 1 (5.3%), 0
(0%), 5 (26.3%), and 5 (26.3%) respectively. Functional outcomes
were poorly documented in 6 patients12–14,18,22.
Table 2
ECT Treatment Characteristics and Outcomes.
Reference # of
patients
Treated
with ECT
Electrode
Positioning
ECT Treatment
Regimen
Other AED
On Board
Electrographic
Seizure Response
Duration of
Response
Adverse
Effects to
ECT
Patient
Outcome
Carrasco et al9 1 NA 6 sessions (3/week) Phenytoin
Diazepam
Carbamazepine
Pentobarbital
Phenobarbital
Complete
resolution
NA NA Completely
recovered
within 1 month
Cline et al10 1 Bifrontotemporal 9 sessions (3/d for 3
consecutive days)
Current=800 mA
Charge=576 mC
Pulse
frequency = 90 Hz
Pulse Width = 1 s
Valproate
Pentobarbital
Levetiracetam
Phenytoin
Oxcarbazepine
Topiramate
Lorazepam
Felbamate
Improvements
with diffusely
slow activity with
a delayed
response over
time
16 months NA Patient
continues to
have focal
seizures.
Signiﬁcant
neurological
deﬁcits from
which there is
slow recovery
Fernandez-
Torre et al11
1 NA NA Phenobarbital
Oxcarbamazepine
Valproate
Clonazepam
Levetiracetam
Carbamazepine
Topiramate
Phenytoin
Lamotrigine
Vigabatrin
Propofol
Midazolam
Thiopental
Lidocaine
Failed NA NA Died
Griesemer
et al12
2 NA 1!
4 total series.
#1 (week 1) 4
sessions over 9d
#2: (week 52) 3
sessions over 3d
#3: (week 82) 3 daily
sessions over 2d
#4: (week 84) 3
sessions in 1d
2!
3 total series
#1 (week 1) 3
sessions over 5d
#2 (week 3) 3
sessions over 2d
#3 (week 5) 3
sessions over 2d
1! Phenobarbital
Phenytoin
Acetazolamide
Clonazepam
Valproate
Gabapentin
Lamotrigine
Felbamate
2!
Gabapentin
Valproate
1! mild
improvement in
seizure frequency
2! transient
reduction in the
number of
spontaneous
seizures
1!
1 year for 1st series,
1 month for 2nd
series. 3rd and 4th
series were
effective for 2
weeks
2!2 weeks
1!
lethargic
between
seizures
2! NA
ECT response
was transient
in both patients
Kamel et al13 3 Bifrontotemporal All 3 patients
received the
following protocol:
4 sessions over 5d
Current = 0.91A
Charge = 507mC
Pulse
frequency = 70 Hz
Pulse Width = 0.5ms
Patient 3 received 2
courses of this
protocol.
1!
Valproate
Levetiracetam
Topiramate
Ketamine
Phenobarbital
Phenytoin
2!
Phenytoin
Levetiracetam
Valproate
Pentobarbital
Ketamine
3!
Phenytoin
Valproate
Topiramate
Phenobarbital
Levetiracetam
Isoﬂurane
Ketamine
1! complete
resolution
2! no response
3!seizures
decreased in
frequency
1! indeﬁnite
2! NA
3! indeﬁnite
1!
retrograde
amnesia
2! NA
3! mild
retrograde
amnesia
1! seizures
resolved
2! died. Multi-
organ
complication
leading to acute
kidney failure
3!continues to
have seizures
(no SE) but is
able to live
independently
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Table 2 (Continued )
Reference # of
patients
Treated
with ECT
Electrode
Positioning
ECT Treatment
Regimen
Other AED
On Board
Electrographic
Seizure Response
Duration of
Response
Adverse
Effects to
ECT
Patient
Outcome
Koong et al14 1 NA Received ECT
sessions 2/week for 6
weeks
NA Transient seizure
cessation
1week. NA Seizures
gradually
reappeared and
patient was
maintained
with weekly
ECT sessions
Lisanby et al15 1 Right
frontotemporal
& Left parietal
5 consecutive daily
sessions
Current = 0.8A
Charge = 576-
3379mC
Pulse frequency = 90-
120 Hz
Pulse Width = 1-
1.4ms
Vigabatrin
Phenobarbital
Nitrazepam
Phenytoin
Midazolam
Phenobarbital
Pentobarbital
Resolution of
continuous
epileptiform
activity
2 months NA SE resolved, but
patient remains
comatose
Moddel et al16 3 NA Patient 1 & 3: 3
sessions
Patient 2: 1 session
1! Midazolam
Propofol
Phenytoin
Valproate
Levetiracetam
Topiramate
Oxycarbazepine
Lidocaine
2!Lorazepam
Phenytoin
Propofol
Valproate
Levetiracetam
Lamotrigine
Topiramate
Lidocaine
Thiopental
3!Lorazepam
Pheyntoin
Propofol
Thiopental
Levetiracetam
Valproate
no response NA NA ECT did not
terminate SE
and functional
outcome was
poor in all
patients
Morales et al17 1 Bilateral 5 consecutive daily
sessions
Current = NA
Charge = 64-1690mC
Pulse frequency = 40-
120 Hz
Pulse Width = 1-
1.1 ms
Lorazapam
Fosphenytoin
Oxycarbezapine
Lamotrigine
Zonisamide
Phenobarbital
Levetiracetam
no response NA None No clinical
improvement.
Patient died 3
months later
Regenold
et al18
1 Bilateral 8 sessions over 16
days
Phenytoin
Phenobarbital
Diazepam
Lorazepam
Carbamazepine
Resolution of SE
after 8th session
6 months None Seizure
disorder was
under control,
but patient
continues to
partial-
complex
seizures
Savard et al19 1 NA NA Oxycarbazine
Levetiracetam
Lacosamide
Clobazam
Topiramate
Valproate
Midazolam
MgSO4
Ketamine
Isoﬂurane
Barbituates
no response NA NA Died 75d post
admission
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Table 2 (Continued )
Reference # of
patients
Treated
with ECT
Electrode
Positioning
ECT Treatment
Regimen
Other AED
On Board
Electrographic
Seizure Response
Duration of
Response
Adverse
Effects to
ECT
Patient
Outcome
Shin et al20 1 Bilateral 3 daily sessions on 2
consecutive days.
This regimen was
repeated twice 5 days
apart
Current = 0.8A
Charge = NA
Pulse frequency = 60-
120 Hz
Pulse Width = 0.37-
2ms
Valproic acid
Topiramate
Levetiracetam
Clobazam
Midazolam
Ketamine
Pentobarbital
NCSE stopped
with generalized
slowing and
bilateral
independent
periodic
lateralized
epileptiform
discharges.
1st round: 2 days
2nd round:
11 weeks
NA Patient
improved in
mental status
and alertness
over 11 weeks
before
suddenly
passing away
Viparelli et al21 1 NA 2 sessions 48 h apart
Current = sinusoidal
Voltage = 110V
Duration= 0.6s
Clonazepam
Diazepam
Phenytoin
Resolution of
spike activity
after 2nd session.
8 years NA Patient
remained
seizure free on
carbamazepine
Wusthoff
et al22
1 NA 10 sessions Pentobarbital
Phenytoin
Levetiracetam
Phenobarbital
Midazolam
Valproate
Topiramate
Pregabalin
Felbamate
Desﬂurane
No response NA NA Patient
responded to
ketogenic diet
Shin et al23 1 Bilateral 3 daily sessions on 2
consecutive days.
This regimen was
repeated twice 5 days
apart
Valproic acid
Topiramate
Levetiracetam
Clobazam
Midazolam
Ketamine
Pentobarbital
Seizure cessation 1st round: 2 days
2nd round: 11
weeks
NA Patient is more
alert but
continues to
have absence
seizures.
ECT = electroconvulsive therapy, AED = anti-epileptic drug, mC = mili-Coulomb, mA = mili-amperes, Hz = Hertz, d = day, ms = mili-seconds, s = seconds, NA = not available. *Shin
et al23 is a meeting abstract which contains the same patient data as Shin et al20. Patient data from Shin et al23 was not included in the ﬁnal data analysis in order to avoid
duplication of data.
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statements on the association of ECT response to seizure
characteristics cannot be made at this time.
3.5. Level of evidence for ECT in RSE
Based on the 14 original articles included in the ﬁnal review, all
fulﬁll Oxford level 4, GRADE D evidence to suggest a potential
impact of ECT on seizure control in the setting of RSE.
Summary of the level of evidence can be seen in Table 3.
4. Discussion
Through our systematic review we identiﬁed 14 original
articles9–22 with a total of 19 patients receiving ECT for RSE. Of
the 19 patients, 15 were adult, and 5 were pediatric. All studies
were retrospective in nature. Seizure reduction/control with the
application of ECT occurred in 11 of the 19 patients (57.9%), with 4
(21.0%) and 7 (36.8%) displaying partial and complete responses
respectively. Seizure control lasted for variable duration, with the
most commonly quoted duration ranging from 2 weeks to 3
months. Three patients had recorded transient adverse events
related to ECT therapy. Data on patient functional outcome was
available in 13 patients, with 10 patients falling into the categories
of dead or severely disabled. In 6 patients there was insufﬁcient
data on functional outcome to allow for GOS scoring. All studies
were an Oxford level 4, GRADE D level of evidence. We can
currently provide Oxford level 4, GRADE D recommendations thatthe application of ECT may provide some impact on seizure control
in the setting of RSE.
A few important points can be seen within our review. First, the
application of ECT appears to have an impacton seizure control in
the setting of RSE within the series identiﬁed. Given the
heterogeneity of the reports we are not able to compare the
impact of ECT in these patients to other therapies. Furthermore, the
exact treatment/stimulation parameters leading to seizure re-
sponse were quite variable within the studies identiﬁed and thus
we can comment on an appropriated treatment regimen at this
time. This is in contrast to the previously published review on the
subject from 2012, in which complete seizure cessation was
documented at 80%24. Second, the anti-epileptic effect of ECT is
present even in cases of prolonged seizure duration. Third, the
reported duration of effect of ECT on seizure control was quite
variable and difﬁcult to interpret, with the most common
therapeutic duration lasting from 2 weeks up to 3 months. Some
patients required repeat treatment with ECT. This highlights the
point that ECT will unlikely be a permanent solution to patients
RSE, but more of a bridging therapy to allow for titration of AED
regimens. As some patients would have been seen in outpatient
follow up during some of these reported time frames, it is difﬁcult
to translate these values to the ‘‘duration of effect’’ for ECT in the
setting of the acute management of RSE. WillECT need to become a
part of outpatient therapy for these individuals with transient
responses to stimulation? Based on current data available, it is
unknown at this time. Fourth, a small number of transient
complications were described, emphasizing the relative safety of
Table 3
Oxford and GRADE level of evidence.
Reference Study type Oxford28 Level of Evidence GRADE29–34 Level of Evidence
Carrasco et al.9 Retrospective Case report 4 D
Cline et al.10 Retrospective Case Report 4 D
Fernandez-Torre et al.11 Retrospective case Report 4 D
Griesemer et al.12 Retrospective Case Series 4 D
Kamel et al.13 Retrospective Case Series 4 D
Koong et al.14 Retrospective Case Report 4 D
Lisanby et al.15 Retrospective Case Report 4 D
Moddel et al.16 Retrospective Case Series 4 D
Morales et al.17 Retrospective Case Report 4 D
Regenold et al.18 Retrospective Case Report 4 D
Savard et al.19 Retrospective Case Report 4 D
Shin et al.20 Retrospective Case Report 4 D
Viparelli et al.21 Retrospective Case Report 4 D
Wusthoff et al.22 Retrospective Case Report 4 D
Shin et al.23 Retrospective Case Report 4 D
* Shin et al.23 is a meeting abstract which contains the same patient data as Shin et al.20. Patient data from Shin et al23 was not included in the ﬁnal data analysis in order to
avoid duplication of data.
F.A. Zeiler et al. / Seizure 35 (2016) 23–32 31this treatment. Finally, patient functional outcomes were poor
with as GOS of 4 and 5 in 26.3% and 26.3% of patients. Only 15.8% of
patients qualiﬁed for a GOS of 1 or 2. Six patients (31.5%) had
insufﬁcient data in the parent reports to accurately determine their
GOS.
Our review has signiﬁcant limitations that require recognition.
First, the small number of studies identiﬁed, all with small patient
populations, makes it difﬁcult to generalize to all RSE. Second, the
retrospective heterogeneous nature of the data makes it difﬁcult
to perform a meaningful meta-analysis. Third, the seizure
response to ECT may not be related entirely to the stimulation
at all, and may be a reﬂection of the combination of multiple AEDs
and therapies working in concert. Fourth, our comments on the
treatment regimen and stimulation parameters of ECT are limited
given the small number of studies and heterogeneity of the
described regimens. Finally, the potential for publication bias in
the articles reviewed is high. It is likely that there are many more
negative results with ECT for RSE that haven’t made it to the
literature.
Currently, the routine use of ECT for seizure control in RSE
cannot be recommended at this time. The results of this review
point to a potential impact that this therapy may have on seizure
control, however further prospective study is warranted. There
exists a need for international databases that document the impact
of therapies in RSE, as they may the understanding of the impact of
ECT on seizure control.
5. Conclusions
Oxford level 4, GRADE D evidence exists to suggest an
improvement in seizure control with ECT application for RSE.
Routine use of ECT cannot be recommended at this time. Further
prospective study of this therapy is required in order to determine
its efﬁcacy in this setting.
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